PPI use linked to increased risk of ischemic stroke, MI

PPI use linked to increased risk of ischemic stroke, MI

(HealthDay)—Proton pump inhibitor (PPI) use is associated with increased risk of first-time ischemic stroke and myocardial infarction (MI), according to a study published online Oct. 12 in the Journal of Internal Medicine.

Thomas S.G. Sehested, M.D., from The Danish Heart Foundation, and colleagues identified all Danish individuals with no prior history of MI or who had elective performed between 1997 and 2012. The authors examined the correlation between current PPI use/dose and the risk of first-time ischemic stroke and MI.

The researchers identified 7,916 and 5,608 MIs among 214,998 individuals during a median follow-up of 5.8 years. After adjustment for age, sex, comorbidities, and concomitant medications, the rates of ischemic stroke and MI were significantly increased with current PPI exposure (hazard ratios, 1.13 and 1.31). High-dose PPI was correlated with elevated rates of ischemic stroke and MI (hazard ratios, 1.31 and 1.43, respectively). There was no significant correlation for histamine H2 receptor antagonist use with ischemic stroke or MI. Compared with non-users, long-term PPI users had 29 and 36 percent greater absolute risks of ischemic stroke and MI, respectively, within a six-month period.

"Use of PPIs was associated with increased risks of first -time ischemic stroke and MI, particularly among long -term users and at high doses," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Explore further

Greater benefit for pioglitazone in high-risk patients post stroke

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Journal of Internal Medicine

Copyright © 2017 HealthDay. All rights reserved.

Citation: PPI use linked to increased risk of ischemic stroke, MI (2017, October 18) retrieved 13 July 2020 from https://medicalxpress.com/news/2017-10-ppi-linked-ischemic-mi.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments